Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 15/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.57 |
| ▸ | TDO2 | P48775 | 3/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15229944 | 0.92 | METAP2 (0.85) | METAP2CYP1A2TDO2IDO1ABL1 | |
| SCHEMBL15230538 | 0.89 | METAP2 (0.80) | METAP2CYP1A2TDO2ALPLIDO1 | |
| SCHEMBL15230173 | 0.89 | METAP2 (1.00) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230125 | 0.88 | METAP2 (0.78) | METAP2CYP1A2TDO2ABL1BCR | |
| SCHEMBL15229965 | 0.87 | METAP2 (0.85) | METAP2CYP1A2TDO2 | |
| SCHEMBL15229871 | 0.87 | METAP2 (1.00) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230502 | 0.85 | METAP2 (0.86) | METAP2CYP1A2TDO2 | |
| SCHEMBL15229865 | 0.82 | METAP2 (0.69) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230237 | 0.81 | METAP2 (0.68) | METAP2CYP1A2TDO2 | |
| SCHEMBL15229839 | 0.81 | METAP2 (0.73) | METAP2CYP1A2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | claimed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | claimed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | claimed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005232-A1 | INDAZOLE DERIVATIVES | GPR119, INSR, INSRR | METAP2 46/4885CYP1A2 6/4885TDO2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.